BioSpace News Archive

As Moderna moves forward with its mRNA vaccine candidate for COVID-19, the U.S. federal government is helping accelerate the potential medication with a $483 million infusion from the Biomedical Advanced Research and Development Authority.

Here’s a look at what’s on the U.S. Food and Drug Administration’s schedule for the next two weeks.

Despite the poor Q1 economic data that is beginning to be released, the equity markets are stabilizing.

A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.

The agency issued a statement saying that it will continue its activities, such as reviewing new drug applications and clinical trial, both COVID-19 and non-COVID-19, applications, “as we do everything possible to maintain continuity of operations in a very dynamic situation.”

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.

Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have.

The Regenstrief Institute and Indiana University are launching a survey to conduct research about COVID-19 symptoms.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces the completion of the pre-submission meeting with the European Medicines Agency for the Company’s lead product LUMEVOQ®.

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease.